Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Mavrakis, K
This trial reinforces the growing role of GLP-1based therapies in reshaping obesity management and highlights the need to integrate them into holistic care strategies in India
KO of Gipr in the AP (Gipr AP-KO ) abolished the ability of acyl-GIP to reduce food intake at the onset of the dark phase in AL-fed animals, using Gipr AP-GFP mice as a control group (Fig
The study is registered with ClinicalTrials.gov, NCT03693430
US$ 22.95
US$ 27.85
US$ 20.38
US$ 22.59
US$ 26.43
US$ 22.07
US$ 28.92
US$ 20.06
US$ 29.12
US$ 25.75
